🇺🇸 FDA
Patent

US 8278348

Chondropsin-class antitumor V-atpase inhibitor compounds, compositions and methods of use thereof

granted A61PA61P13/00A61P15/08

Quick answer

US patent 8278348 (Chondropsin-class antitumor V-atpase inhibitor compounds, compositions and methods of use thereof) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Oct 02 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P13/00, A61P15/08, A61P19/08, A61P19/10